Benitec Biopharma Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Benitec Biopharma Inc 's ROA in the fourth quarter of 2026?
Benitec Biopharma Inc recorded a cumulative net loss of $-46 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -20.91%.

However, within the Healthcare sector 437 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3709, from total ROA ranking in the third quarter of 2026 at 4522.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	295.06 %	77.83 %	90.75 %	178.06 %	90.75 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-46	-42	-44	-42	-38
Return On Assets (TTM)	-20.91 %	-28.78 %	-35.6 %	-37.33 %	-46.56 %
BNTC's Total Ranking	# 3709	# 4522	# 3998	# 4039	# 4145
Total Assets (TTM) in million	393	187	100	191	100
Seq. Total Assets Change	110.4 %	87.77 %	-47.92 %	92.02 %	-5.29 %
Seq. Net Income Change	-	-	-	-	-

BNTC's 5 Years Annual ROA >> Back to BNTC Management Effectiveness >> Compare BNTC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 169
Sector	# 438
Overall	# 3644

Return On Assets Statistics
High	Average	Low
14.93 %	-102.33 %	-212.79 %
(Jun 30 2019)		(Jun 30 2023)

Financial Statements
Benitec Biopharma Inc 's Assets	$ 393 million	BNTC's Balance sheet
Benitec Biopharma Inc 's Income	$ -13 million	Quarterly BNTC's Income Statement
BNTC's Income by Division		See BNTC's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	295.06 %	90.75 %	1069.58 %	-25.26 %	-72.06 %
Total Assets in million	393	100	52	4	6
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-46	-38	-22	-20	-18
Annual Return On Assets	-11.58 %	-38.07 %	-42.85 %	-438.22 %	-304.84 %

BNTC's 5 Years Annual ROA >> Back to BNTC Management Effectiveness >> Compare BNTC ROA to its Competitors

More Return On Assets Ratios
BNTC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BNTC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BNTC's Competitors
Subscribers only: Roa for Benitec Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for BNTC's Customers

You may also want to know
BNTC's Roi	BNTC's Inventory Turnover Ratio	BNTC's Growth Rates	BNTC's Dividend Comparisons
	BNTC's Profitability Ratios	BNTC's Asset Turnover Ratio	BNTC's Dividend Growth
BNTC's Roe	BNTC's Valuation Ratios	BNTC's Financial Strength Ratios	BNTC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-15T11:48:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.